These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
339 related items for PubMed ID: 7858534
1. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study. Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL. Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534 [Abstract] [Full Text] [Related]
2. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS. Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091 [Abstract] [Full Text] [Related]
3. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I. Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380 [Abstract] [Full Text] [Related]
5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR. Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [Abstract] [Full Text] [Related]
6. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W. Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474 [Abstract] [Full Text] [Related]
7. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD. Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973 [Abstract] [Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB. Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [Abstract] [Full Text] [Related]
9. Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation. Broun ER, Tricot G, Akard L, Nichols C, Cheerva A, Jansen J. Bone Marrow Transplant; 1990 May; 5(5):341-4. PubMed ID: 2190660 [Abstract] [Full Text] [Related]
10. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease. Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A. Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918 [Abstract] [Full Text] [Related]
11. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Geller RB, Myers S, Devine S, Larson RA, Williams SF, Park CL, O'Toole K, Chandler C, Topper RL. Bone Marrow Transplant; 1992 Jan 01; 9(1):41-7. PubMed ID: 1543948 [Abstract] [Full Text] [Related]
12. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Gryn J, Johnson E, Goldman N, Devereux L, Grana G, Hageboutros A, Fernandez E, Constantinou C, Harrer W, Viner E, Goldberg J. Bone Marrow Transplant; 1997 Feb 01; 19(3):221-6. PubMed ID: 9028549 [Abstract] [Full Text] [Related]
13. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Kröger N, Hoffknecht M, Hänel M, Krüger W, Zeller W, Stockschläder M, de Wit M, Weh HJ, Kabisch H, Erttmann R, Zander AR. Bone Marrow Transplant; 1998 Jun 01; 21(12):1171-5. PubMed ID: 9674847 [Abstract] [Full Text] [Related]
14. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A. Bone Marrow Transplant; 1990 Feb 01; 5(2):99-103. PubMed ID: 2310878 [Abstract] [Full Text] [Related]
15. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL, Hahn T. Bone Marrow Transplant; 2008 Apr 01; 41(7):613-9. PubMed ID: 18071290 [Abstract] [Full Text] [Related]
16. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR. Ann Hematol; 2002 Feb 01; 81(2):96-102. PubMed ID: 11907790 [Abstract] [Full Text] [Related]
17. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE. J Clin Oncol; 1990 Apr 01; 8(4):648-56. PubMed ID: 2313334 [Abstract] [Full Text] [Related]
18. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C. J Clin Oncol; 1993 Jul 01; 11(7):1329-35. PubMed ID: 8315430 [Abstract] [Full Text] [Related]
19. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH. Eur J Haematol Suppl; 2001 Jul 01; 64():28-32. PubMed ID: 11486397 [Abstract] [Full Text] [Related]
20. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL. N Engl J Med; 1995 Dec 07; 333(23):1540-5. PubMed ID: 7477169 [Abstract] [Full Text] [Related] Page: [Next] [New Search]